These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 19486542)

  • 1. "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence.
    Savarino A; Mai A; Norelli S; El Daker S; Valente S; Rotili D; Altucci L; Palamara AT; Garaci E
    Retrovirology; 2009 Jun; 6():52. PubMed ID: 19486542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors.
    Banga R; Procopio FA; Cavassini M; Perreau M
    J Virol; 2016 Feb; 90(4):1858-71. PubMed ID: 26656693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitors induce complex host responses that contribute to differential potencies of these compounds in HIV reactivation.
    Beliakova-Bethell N; Mukim A; White CH; Deshmukh S; Abewe H; Richman DD; Spina CA
    J Biol Chem; 2019 Apr; 294(14):5576-5589. PubMed ID: 30745362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection.
    Reuse S; Calao M; Kabeya K; Guiguen A; Gatot JS; Quivy V; Vanhulle C; Lamine A; Vaira D; Demonte D; Martinelli V; Veithen E; Cherrier T; Avettand V; Poutrel S; Piette J; de Launoit Y; Moutschen M; Burny A; Rouzioux C; De Wit S; Herbein G; Rohr O; Collette Y; Lambotte O; Clumeck N; Van Lint C
    PLoS One; 2009 Jun; 4(6):e6093. PubMed ID: 19564922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quiescence Promotes Latent HIV Infection and Resistance to Reactivation from Latency with Histone Deacetylase Inhibitors.
    Painter MM; Zaikos TD; Collins KL
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29021396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitors containing a benzamide functional group and a pyridyl cap are preferentially effective human immunodeficiency virus-1 latency-reversing agents in primary resting CD4+ T cells.
    Kobayashi Y; Gélinas C; Dougherty JP
    J Gen Virol; 2017 Apr; 98(4):799-809. PubMed ID: 28113052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isoform-Selective Versus Nonselective Histone Deacetylase Inhibitors in HIV Latency Reversal.
    Boateng AT; Abaidoo-Myles A; Bonney EY; Kyei GB
    AIDS Res Hum Retroviruses; 2022 Aug; 38(8):615-621. PubMed ID: 35778852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression.
    Zaikos TD; Painter MM; Sebastian Kettinger NT; Terry VH; Collins KL
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29298886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors.
    Archin NM; Keedy KS; Espeseth A; Dang H; Hazuda DJ; Margolis DM
    AIDS; 2009 Sep; 23(14):1799-806. PubMed ID: 19590405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel selective histone deacetylase I inhibitor CC-4a activates latent HIV-1 through NF-κB pathway.
    Lu W; Yang C; Xu X; Chen C; Hou X; Fang H; Liu S
    Life Sci; 2021 Feb; 267():118427. PubMed ID: 32941894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitor chidamide promotes reactivation of latent human immunodeficiency virus by introducing histone acetylation.
    Kuai Q; Lu X; Qiao Z; Wang R; Wang Y; Ye S; He M; Wang Y; Zhang T; Wu H; Ren S; Yu Q
    J Med Virol; 2018 Sep; 90(9):1478-1485. PubMed ID: 29704439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic Activation of Latent HIV-1 Expression by Novel Histone Deacetylase Inhibitors and Bryostatin-1.
    Martínez-Bonet M; Clemente MI; Serramía MJ; Muñoz E; Moreno S; Muñoz-Fernández MÁ
    Sci Rep; 2015 Nov; 5():16445. PubMed ID: 26563568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells.
    Wightman F; Lu HK; Solomon AE; Saleh S; Harman AN; Cunningham AL; Gray L; Churchill M; Cameron PU; Dear AE; Lewin SR
    AIDS; 2013 Nov; 27(18):2853-62. PubMed ID: 24189584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short Communication: The Broad-Spectrum Histone Deacetylase Inhibitors Vorinostat and Panobinostat Activate Latent HIV in CD4(+) T Cells In Part Through Phosphorylation of the T-Loop of the CDK9 Subunit of P-TEFb.
    Jamaluddin MS; Hu PW; Jan Y; Siwak EB; Rice AP
    AIDS Res Hum Retroviruses; 2016 Feb; 32(2):169-73. PubMed ID: 26727990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The development of immune-modulating compounds to disrupt HIV latency.
    Remoli AL; Marsili G; Battistini A; Sgarbanti M
    Cytokine Growth Factor Rev; 2012; 23(4-5):159-72. PubMed ID: 22766356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs.
    Abner E; Stoszko M; Zeng L; Chen HC; Izquierdo-Bouldstridge A; Konuma T; Zorita E; Fanunza E; Zhang Q; Mahmoudi T; Zhou MM; Filion GJ; Jordan A
    J Virol; 2018 May; 92(10):. PubMed ID: 29343578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of IL-15 and latency reversing agent combinations in the reactivation and NK cell-mediated suppression of the HIV reservoir.
    Covino DA; Desimio MG; Doria M
    Sci Rep; 2022 Nov; 12(1):18567. PubMed ID: 36329160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
    Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
    Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat.
    Maxwell JW; Falcinelli SD; Nefedov A; Dorfmeier C; Wu G; Dewey M; Webber AL; Archin NM; Margolis DM; Hazuda DJ; Barnard RJO; Howell BJ
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32295913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
    Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
    J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.